Jinzi Wu
Chief Executive Officer chez ASCLETIS PHARMA INC.
Fortune : 103 M $ au 31/03/2024
Profil
Jinzi J.
Wu is the founder of Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
(founded in 2011) and Gannex Pharma Co Ltd.
(founded in 2019).
Dr. Wu is also the founder of Ascletis Pharma, Inc. Dr. Wu's current job positions include Chief Executive Officer & Director at Ascletis BioScience Co., Ltd.
(since 2013), Chief Executive Officer & Director at Ascletis Xinnuo Medicine Co., Ltd (since 2018), Director at Sagimet Biosciences, Inc. (since 2019), Director at Ascletis Pharma China Co., Ltd.
(since 2018), Director at Soundridge Pharmaceuticals (Hong Kong) Co., Ltd.
(since 2019), Member at The BayHelix Group, and Manager at Gannex LLC (since 2020).
Dr. Wu's former job positions include Principal at Immunex Corp.
(1992-2002), Principal at Novartis AG (1992-2002), Vice President at GSK Plc, Principal at Sanofi India Ltd.
(1992-2002), Senior Scientist at Novartis Pharmaceuticals Corp.
(1997-2000), Vice President-Preclinical & Basic Research at Ambrilia Biopharma, Inc. (2004-2008), Vice President-Research & Development at PhageTech, Inc. (2002-2004), and Vice President at Ascletis Pharmaceuticals Co., Ltd.
(2014-2021).
Dr. Wu's education includes a doctorate degree from the University of Arizona (conferred in 1996) and undergraduate and graduate degrees from Nanjing University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ASCLETIS PHARMA, INC.
50,79% | 05/03/2024 | 514 393 664 ( 50,79% ) | 94 M $ | 31/03/2024 |
| 18/07/2023 | 1 654 701 ( 7,74% ) | 9 M $ | 31/03/2024 |
Postes actifs de Jinzi Wu
| Sociétés | Poste | Début |
|---|---|---|
| ASCLETIS PHARMA INC. | Chief Executive Officer | - |
| SAGIMET BIOSCIENCES INC. | Director/Board Member | 01/02/2019 |
| Ascletis Pharma China Co., Ltd. | Director/Board Member | 01/03/2018 |
| Gannex LLC | Corporate Officer/Principal | 01/10/2020 |
| Gannex Pharma Co Ltd. | Chief Executive Officer | 01/01/2019 |
| Soundridge Pharmaceuticals (Hong Kong) Co., Ltd. | Director/Board Member | 01/04/2019 |
| Ascletis Xinnuo Medicine Co., Ltd | Chief Executive Officer | 01/07/2018 |
| Ascletis BioScience Co., Ltd. | Chief Executive Officer | 01/04/2013 |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
 Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Chief Executive Officer | - |
| ░░░ ░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Jinzi Wu
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Jinzi Wu
| University of Arizona | Doctorate Degree |
| Nanjing University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| NOVARTIS AG | Health Technology |
| GSK PLC | Health Technology |
| SANOFI INDIA LIMITED | Health Technology |
| SAGIMET BIOSCIENCES INC. | Health Technology |
| ASCLETIS PHARMA INC. | Health Technology |
| Entreprise privées | 13 |
|---|---|
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Health Technology |
| The BayHelix Group | |
PhageTech, Inc.
 PhageTech, Inc. Miscellaneous Commercial ServicesCommercial Services PhageTech, Inc. provides medical services. The firm develops bacteriophage sensors related tests for detecting analytes in urine, blood, and other body fluids. Its technology is used for advanced diagnostics, such as early stage cancer detection, drug dosage monitoring, and time sensitive diseases and conditions. The company was founded by Richard W. Henson, Gregory Weiss, and Reginald Penner in 2014 and is headquartered in Irvine, CA. | Commercial Services |
| Ascletis BioScience Co., Ltd. | |
| Gannex Pharma Co Ltd. | |
| Ascletis Pharma China Co., Ltd. | |
| Ascletis Xinnuo Medicine Co., Ltd | |
| Soundridge Pharmaceuticals (Hong Kong) Co., Ltd. | |
| Gannex LLC | |
| Ascletis Pharmaceuticals Co., Ltd. |
